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Bashir M. Matata and Manuel Galin˜anes
The metabolism of nitric oxide (NO) during cardiac
surgery is unclear. We studied the effect of diabetes on
NO metabolism during cardiac surgery in 40 subjects
(20 with diabetes and 20 without diabetes). The pa-
tients were randomized to receive an infusion of physi-
ological saline or nitroglycerin (GTN) at 1 g  kg–1 
min–1 starting 10 min before the initiation of cardiopul-
monary bypass and then continuing for a period of 4 h.
Blood and urine samples were collected at several time
points for up to 8 h. NO metabolites were determined by
the measurement of nitrate/nitrite (NOx, mol/mmol
creatinine) and cyclic guanosine monophosphate (cGMP,
nmol/mmol creatinine) in plasma and urine. Plasma in-
sulin levels were also determined at selected time points.
Plasma NOx levels before surgery were significantly
elevated in the group with diabetes compared with the
group without diabetes (P < 0.001), and values were
further increased during surgery in the former (P 
0.005) but not in the latter (P  0.8). The greater plas-
ma NOx values in patients with diabetes were matched by
commensurate elevations in plasma cGMP levels (P 
0.01). Interestingly, infusion of GTN, an NO donor,
significantly reduced plasma NOx (P < 0.001) and its
urine elimination (P < 0.001) in patients with diabetes
without reducing plasma cGMP levels (P  0.89). Cardiac
surgery increased plasma insulin in patients with and
without diabetes; this increase was delayed by the infu-
sion of GTN, but it was not related to the changes in NO
production. In conclusion, NO production during cardiac
surgery is increased in patients with diabetes, and this
elevation can be blunted by the infusion of GTN in a rapid
and reversible manner. Diabetes 50:2603–2610, 2001
Diabetes is recognized as a major independentrisk factor for cardiovascular disease (1). Inaddition, patients with diabetes undergoing car-diac surgery have a greater rate of perioperative
complications and increased mortality than those without
diabetes (2,3), but the reason for this is unknown. Diabe-
tes is associated with altered endothelial vascular re-
sponses (4), and modifications in nitric oxide (NO)
metabolism may play a role. This thesis finds support in
the observation that diabetes affects basal NO metabolism
(5). We have also recently demonstrated (6) that the
provision of exogenous NO during cardiac surgery influ-
ences oxidative stress and the inflammatory response to
cardiopulmonary bypass (CPB), effects that are more
prominent in patients with diabetes than in those without
diabetes. NO, synthesized by NO synthase (NOS) from a
terminal guanidino group of L-arginine (7), relaxes vascu-
lar smooth muscle and inhibits platelet aggregation and
adhesion via the second messenger cyclic guanosine
monophosphate (cGMP) (8), and it has also been impli-
cated in the pathophysiology of a number of cardiovascu-
lar diseases, including atherosclerosis (9), septic shock
(10), inflammation (11), oxidative stress (12), and isch-
emia/reperfusion injury (13). NO is rapidly oxidized to
nitrate and nitrite (14), and it is subsequently eliminated
by excretion into the urine (15). Recent studies have
shown that there is an uptake of NO into the erythrocytes
and that its conversion to nitrate/nitrite (NOx) and methe-
moglobin is a major pathway of degradation for endog-
enously formed NO (16). NOx may then enter the plasma
to be eliminated via the kidneys. However, it is unclear
how NO metabolism may be affected by diabetes and
cardiac surgery.
The metabolism of NO is rapid, and this may pose
difficulties for the assessment of NO production. To over-
come this, a possibility may be to determine the stable NO
metabolites NOx and the second messenger cGMP in
plasma and in urine, as described by Wennmalm et al. (16),
with values corrected by creatinine clearance to take into
account changes in renal excretory function, as advocated
by Bo¨ger et al. (17). In the present study, using this
approach, we assessed NOx and cGMP values in plasma
and urine to investigate the effect of diabetes on the
metabolism of NO during cardiac surgery and determine
whether this is affected by the administration of the NO
donor nitroglycerin (GTN). Because insulin increases NOS
expression (18) and NO production (19–21), insulin
plasma levels were also determined.
RESEARCH DESIGN AND METHODS
Study groups and selection criteria. The study was conducted in accor-
dance with the principles expressed in the Declaration of Helsinki, and local
ethical committee approval was obtained. Informed written consent was
authorized by all participating individuals after the nature of the investigation
was explained to them. A total of 170 patients were operated on by one
surgeon (M.G.) during a 12-month period. Individuals with valvular disease,
ventricular aneurysm, peripheral vascular disease, carotid stenosis, heart
failure, and poor left ventricular function were excluded from the study. Only
86 patients, all undergoing elective coronary bypass graft surgery, met the
selection criteria, and 40 of these patients (20 with diabetes and 20 without
diabetes) consented to take part in the study. The patients were blinded as to
the mode of treatment, and data from all of the patients taking part in the
study were included in the final analysis. Patients taking part in the study
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(both with or without diabetes) were assigned numbers, and a computer
random number generator was used to create two groups. One group received
physiological saline solution, and the other received the NO donor GTN,
which was infused at a rate of 1 g  kg–1  min–1 starting 10 min before the
initiation of CPB and then continued for 4 h.
Before surgery, blood glucose levels were well controlled by either insulin
(n  10) or oral antidiabetic therapy (n  10) in all patients, as shown by the
HbA1 values (range 7.2–9.7% with a mean value of 8.5  0.3% compared with
the normal 4–8.5% normal range). Patients with diabetes attended the
Diabetes Clinic in the Department of Endocrinology at the University Hospital
of Leicester, Leicester General Hospital, for treatment. The disease classifi-
cation was undertaken in accordance with the revised American Diabetes
Association (22) and the World Health Organization criteria (23). During the
study, the infusion of insulin to control blood glucose commenced immedi-
ately after the termination of CPB in all patients with diabetes and was
maintained for 48–72 h. Blood glucose levels were monitored periodically, and
they were kept under control by a sliding scale regime for insulin administra-
tion using a stock concentration of 1 IU/ml insulin (Actrapid) suspended in
normal saline. When blood glucose was 0–4, 4–6, 6–8, 8–10, 10–12, 12–14,
and 14 mmol/l, patients were given a corresponding insulin infusion of 0, 2,
4, 6, 8, 10, or 12 ml/h, respectively. Hemoglobin levels were also monitored
periodically, and blood transfusion was performed to maintain values 10
mg/dl.
Blood and urine sampling. Arterial blood samples were collected at the
following time points: before the induction of anesthesia, before the initiation
of CPB (time 0), and 0.5, 1, 2, 4, and 8 h thereafter. Samples were collected into
sterile EDTA tubes and centrifuged immediately at 1,500g for 12 min at 4°C.
The resultant plasma was aliquoted and stored at 80°C until analysis.
Immediately before the induction of anesthesia, a urine catheter (Cobe
CML; Cobe Laboratories, Gloucester, U.K.) was inserted into the bladder and
connected to a reservoir bag. The initial urine samples were discarded, and
samples for analysis were collected at time 0–1, 1–2, 2–4, and 4–8 h after the
initiation of CPB and immediately snap frozen and stored at 80°C until
analysis.
Anesthesia. The administration of anesthesia was in accordance with
institutional guidelines. All of the volunteers received morphine (10.0 mg) and
prochlorperazine (12.5 mg) administered intramuscularly at least 1 h before
surgery. Central venous and radial artery cannulae were inserted under local
anesthesia (1% lidocaine) and with midazolam sedation (3.0–4.0 mg i.v.).
Anesthesia was induced with an infusion of propofol (8.0 mg  kg–1  h–1 i.v.)
and with fentanyl (1.0 mg i.v.) and pancuronium (12.0 mg i.v.). Anesthesia was
then maintained by continuous infusion of propofol (4.0 mg  kg–1  h–1 i.v.).
Hypotension was controlled by intravenous infusion of fluids or 0.5 mg
metaraminol, with increments where appropriate. Heparin (300 IU/kg body
wt) was administered in all study patients just before aortic cross-clamping to
achieve an activated clotting time of 450 s. A further 5,000 IU heparin were
given in the bypass prime. Morphine (5.0 mg i.v.) and diclofenac (100.0 mg
i.v.), a nonsteroidal nonnarcotic drug, were given to treat pain when required
and if not contraindicated.
Surgery. After the induction of anesthesia and the systemic application of
heparin, CPB was initiated in a standard fashion under conditions of mild
body hypothermia (32°C). Briefly, CPB was composed of a roller pump circuit
(Sto¨ckert Instrumente, Munich, Germany), a hollow fiber polypropylene
oxygenator with an incorporated cardiotomy reservoir (Cobe CML), and
plasticized polyvinyl chloride tubing. The pump was primed with 1.4 l
Hartmann’s solution and used at a flow rate of 2.4 l  min–1  m–2 body surface
area. The coronary bypass grafts were performed using intermittent periods of
ischemia without using cardioplegic solutions. Heparin was reversed after
bypass by the administration of 3.0 mg/kg protamine.
Measurement of NOx. Plasma and urine samples were assayed for NOx, the
stable end product of NO, by using a commercially available kit (Cayman
Chemical, Ann Arbor, MI). Briefly, the plasma and urine samples were first
filtered through a 0.45-m Minisart column (Amersham, U.K.). The filtrate was
incubated with nitrate reductase and NADH as an enzyme cofactor for 3 h at
room temperature to reduce nitrate to nitrite. The total nitrite (NOx) was then
analyzed by reacting the samples with Griess reagent and measuring the
absorbance of each sample at 540 nm. The amounts of NOx in plasma and
urine were calculated from a known concentration range of a standard curve
obtained by enzymatic conversion of sodium nitrate to sodium nitrite. To rule
out a potential interfering effect of GTN on the measurement of NOx in
plasma, pooled plasma obtained from 10 healthy subjects was spiked with 100
mol/l nitrate. In the presence and absence of 10 mol/l GTN, the assay
detected 116 and 110 mol/l of NOx in the plasma, respectively, indicating a
lack of effect of GTN on the assay. The intra- and interassay coefficient of
variation of the NOx assay in plasma was 9.0 and 9.2%, respectively. The
detection limit of the NOx assay was 2.5 mol/l, and regression coefficients for
the standard curves ranged between 0.98 and 0.999.
Measurement of cGMP. Plasma and urine cGMP were measured by a
competitive enzyme immunoassay kit (Cayman Chemical). In plasma, cGMP
was at first extracted after precipitation with cold ethanol. After centrifuga-
tion at 1,500g for 10 min, the resultant supernatant was collected into clean
test tubes. The supernatant was dried under a stream of nitrogen before
resuspension in phosphate buffer. Urine samples were diluted 100 times with
phosphate buffer and centrifuged at 2,500g at 4°C for 10 min. To enhance the
sensitivity of the assay, all of the samples and standards were acetylated
before the assay by the addition of 4 mol/l potassium hydroxide followed by
acetic anhydride (5:1 ratio).
The assay is based on the competition between free cGMP and a cGMP
tracer (cGMP linked to an acetylcholinesterase molecule) for a limited
number of cGMP-specific rabbit antiserum binding sites. Thus, the amount of
cGMP tracer that is able to bind to the rabbit antiserum is inversely
proportional to the concentration of free cGMP in plate wells. A constant
tracer concentration was maintained, whereas the concentration of free
cGMP (standard and samples) was varied. The resultant rabbit antiserum–
cGMP complex (either free or tracer) binds to a mouse monoclonal anti-rabbit
antibody that has been previously attached to the plate wells after 18 h
incubation at room temperature. After washing to remove any unbound
reagents, Ellman’s reagent (containing the substrate to acetylcholinesterase)
was added to the wells. The product of this enzymatic reaction has a distinct
yellow color and absorbs strongly at 412 nm. The color intensity was
proportional to the amount of cGMP tracer bound to the well, which in turn
was inversely proportional to the free cGMP present in the well during the
incubation. As before, to investigate a potential interfering effect of GTN on
the measurement of cGMP in plasma, pooled plasma obtained from 10 healthy
subjects was spiked with 100 pmol/ml cGMP. In the extracted supernatants,
the assay detected 94 and 92 pmol/ml of cGMP in the presence and absence of
10 mol/l GTN, respectively, indicating a lack of effect of GTN on the assay.
The detection limit of the cGMP assay was 0.09 pmol/ml and the intra- and
interassay coefficient of variation was 9 and 9.7%, respectively.
Measurement of creatinine. To minimize the influence of changes in renal
excretory function, NOx and cGMP values were corrected for creatinine
concentration. Creatinine concentration was determined by a colorimetric
assay from Sigma Chemicals (Poole, Dorset, U.K.). The assay was based on
the reaction between creatinine and alkaline picrate, with a resulting yellow/
orange color. Under acid conditions creatinine-picrate color fades faster than
interfering chromogens. Therefore, measurement of the difference in color
intensity at or near 500 nm before and after acidification is proportional to
creatinine concentration. The resultant plasma content and urinary excretion
of NOx and cGMP were corrected by creatinine concentration expressed as
micromoles per millimole and picomoles per millimoles creatinine, respec-
tively, as described previously (16,17). Creatinine and nitrate clearances were
calculated as follows: clearance  urine flow (ml/min)  urinary concentra-
tion (mol/l) ÷ plasma concentration (mol/l). Pooled plasma with mean
creatinine levels of 1.1–6.9 mg/dl assayed by this method on 10 separate
occasions produced standard deviations of 0.12–0.25 mg/dl and coefficients of
variance of 10.9–3.6%.
Measurement of plasma insulin. Blood glucose was determined by a
glucose-oxidase method (Unimate 5 Glucose HK; Roche, Basel, Switzerland)
using a Vitros 250 autoanalyzer (Orthoclinical Diagnostics, Buckinghamshire,
U.K.). Plasma insulin was determined by an enzyme-linked immunosorbent
assay for human insulin (DRG International, Mountainside, NJ). The minimum
detectable concentration of insulin estimated by this assay was 0.15 IU/ml.
The intra- and interassay coefficient of variance ranged from 3 to 5.3 and 5.6
to 9.8%, respectively. There was no evidence of cross-reactivity with pro-
insulin measurement in this assay.
Statistical analysis. All of the data are presented as the means  SE of
means in plots of values against time in hours (Figs. 1–5). For the purpose of
statistical comparisons, each parameter value plot against time in hours from
the start of the study for each subject, and the area under the curve (AUC) was
calculated as the primary measure of outcome. There was evidence of positive
skewness in some of the raw data-time points, and for this reason logarithm
transformation was used to ensure nearly equal variability in the groups being
compared. The main analysis is a two-way analysis of variance of the AUC
(calculated on the log10 scale) to assess the apparent effect on outcome by
GTN, diabetes, and any corresponding interaction. The results were presented
as the difference between groups in the mean value of AUC, with the
corresponding 95% CIs, and P values 5% were considered to be of statistical
significance. A secondary analysis was then carried out to validate the
statistical significance of these results using the program Proc Mixed in the
computer package SAS to fit an autocorrelation for repeated measures. The
correlation of any two measurements made on the same subject was assumed
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to be d, where d is the intervening period of time and  is common to all
subjects.
RESULTS
Demographic data. As shown in Table 1, the clinical
characteristics and perioperative data were similar in all
study groups. Table 2 shows that the medication adminis-
tered to patients before surgery was also similar in all
study groups, with the exception of the antidiabetic treat-
ment. All of the patients with diabetes had the type 2 form
of the disease. The results were similar for the patients
with diabetes regardless of whether they were on insulin
and, because of this, the values are presented together
without distinction of the treatment for the control of
diabetes.
NOx
In plasma. The results shown in Fig. 1A and B demon-
strate that the NOx mean plasma values at baseline (i.e.,
preanesthesia) were twofold greater in patients with dia-
betes compared with those without diabetes (P  0.001).
They also show that NOx values were not significantly
affected by cardiac surgery (e.g., the first 2 h of sampling)
in patients without diabetes, whereas they were signifi-
cantly (P  0.02) elevated in patients with diabetes.
Interestingly, the infusion of GTN significantly (P  0.003)
reduced plasma NOx only in patients with diabetes.
In urine. Figure 2A and B shows that the urinary excre-
tion of NOx was greater in patients with diabetes com-
pared with those without diabetes during the first hour of
surgery (P  0.01), although the overall urinary excretion
of NOx over the duration of the study was similar in both
study groups (P  0.83). GTN infusion, however, signifi-
cantly reduced urinary NOx in both groups (P  0.005 in
the group with diabetes and P 0.002 in the group without
diabetes).
Plasma creatinine clearance. Table 3 shows the results
for plasma creatinine clearance, which are presented as
ratios of geometric means of AUCs over the entire study
period. The results show that plasma creatinine clearance
is similar in the two groups (P  0.5) and that the infusion
of GTN had no significant effect on creatinine clearance in
both groups of patients (P 0.9 in the group with diabetes
and P  0.14 in the group without diabetes).
Plasma NOx clearance. Table 3 also shows the results
with regard to plasma NOx clearance. Plasma NOx clear-
ance was found to be influenced by diabetes, with values
significantly lower (P  0.002) in patients with diabetes
than in those without diabetes. On the other hand, GTN
significantly reduced (P  0.02) plasma NOx clearance in
patients with diabetes but had no significant effect on
patients without diabetes (P  0.3). These results, taken
together with the unaffected urinary NOx excretion and
plasma creatinine clearance shown above, suggest that the
increase in plasma NOx in patients with diabetes repre-
sents a real increase in NO production that is not readily
eliminated by the kidneys.
cGMP
In plasma. Figure 3A and B shows that, in contrast with
the higher levels in plasma NOx in patients with diabetes,
cGMP plasma mean values were similar in the two patient
groups before anesthesia. They also show that as with
FIG. 1. Changes in plasma NOx before (PA, before anesthesia), during
(first 2 h of sampling), and after cardiac surgery in patients without
diabetes (A) and with diabetes (B) receiving an infusion of saline or
GTN at a rate of 1 g  kg–1  min–1 starting 10 min before the institution
of CPB and then maintained for a period of 4 h after the initiation of
CPB. Values were expressed as the arithmetic mean of 10 patients per
group, and bars represent the SE.
TABLE 1
Clinical characteristics and perioperative data
Without diabetes With diabetes
PSaline GTN Saline GTN
Age (years) 70.1 2.6 68.9 3.5 65.3 2.2 64.1 3.8 0.13
M/F 8/2 9/1 8/2 8/2 0.92
Angina class (CCS) 2.7 0.2 2.9 0.2 3.0 0.3 2.9 0.2 0.64
No. of grafts per subject 2.7 0.2 3.3 0.3 3.0 0.2 3.1 0.3 0.35
Ischemia time (min) 36.8 4.2 44.6 6.6 44.1 3.8 47.8 8.4 0.14
Bypass time (min) 81.5 10.5 91.8 11.1 88.2 7.6 92.4 11.1 0.08
Data are arithmetic means  SE. CCS, Canadian Cardiovascular Society.
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NOx, the effect of cardiac surgery on cGMP values was not
statistically significant in patients without diabetes, but
that it caused a significant increase in the early phase of
surgery in patients with diabetes (47  6 vs. 102  12
mol/mmol creatinine, respectively; P  0.005). However,
the ratios of geometric means of AUC for the overall
plasma cGMP values were not significantly different (P 
0.3) between the two groups during the entire study
period. Importantly, GTN caused a significant increase in
the AUC mean values for plasma cGMP in patients without
diabetes (P  0.001), whereas it had no significant (P 
0.89) effect in patients with diabetes.
In urine. As a reflection of the results on plasma cGMP,
Fig. 4A and B shows that surgery increased urinary cGMP
excretion between 1 and 4 h in patients with diabetes,
whereas it had no marked effect in the group without
diabetes. In addition, ratios of the AUC for the entire study
period further indicate that urinary cGMP excretion was
significantly greater (P  0.02) in the group with diabetes
(3,854  17) compared with the group without diabetes
(2,612  13). These figures also show that the infusion of
GTN resulted in an early increase in cGMP excretion in the
two study groups (P  0.001). This was followed by a
period of no further significant increase in both study
groups (P  0.5 in the group with diabetes and P  0.9 in
the group without diabetes).
Plasma cGMP clearance. The results shown in Table 3
indicate that the mean AUC for cGMP clearance was
significantly greater (P  0.05) in patients with diabetes
compared with those without diabetes. In addition, GTN
infusion significantly reduced cGMP clearance in both
study groups (P  0.04 and P  0.05, respectively), an
effect that may be responsible, at least in part, for the
plasma cGMP elevation seen in patients without diabetes.
Plasma insulin. Figure 5A and B shows that cardiac
surgery induces a significant increase in plasma insulin in
patients without diabetes and a still greater increase in
those with diabetes that peaked at 1 h after the initiation of
CPB. Interestingly, this rise in plasma insulin was delayed
but not suppressed by the infusion of GTN in both groups
of patients. There was no further significant increase in
insulin levels after the administration of exogenous insu-
lin.
Blood glucose. As seen in Table 4, despite the changes in
plasma insulin, blood glucose levels remained within the
same range throughout the entire study period in both
groups of patients; however, values were more elevated in
patients with diabetes than in patients without diabetes.
DISCUSSION
The present study has shown for the first time that cardiac
surgery markedly affects the NO metabolism in patients
with diabetes. Although plasma NOx values were already
significantly elevated before surgery in the group with
diabetes as compared with those without diabetes, further
increases occurred during surgery in the former but not in
FIG. 2. Changes in urinary NOx excretion during (first 2 h of sampling)
and after cardiac surgery in patients without diabetes (A) and with
diabetes (B) receiving an infusion of saline or GTN at a rate of 1 g 
kg–1  min–1 starting 10 min before the institution of CPB and then
maintained for a period of 4 h after the initiation of CPB. Values were
expressed as the arithmetic mean of 10 patients per group, and bars
represent the SE.
TABLE 2
Preoperative medication
Without
diabetes
With
diabetes
PSaline GTN Saline GTN
Nitrates 8 7 8 8 0.94
	-Blockers 8 5 6 6 0.59
ACE inhibitors 5 3 3 6 0.46
KATP channel openers 2 3 1 0 0.29
Ca2
 channel antagonists 10 6 9 8 0.11
Insulin 0 0 4 6 0.01
Oral antidiabetics 0 0 6 4 0.01
In each group, n  10 patients. KATP, ATP-sensitive K

 channel.
TABLE 3
Ratios of geometric means for AUC with the corresponding 95%
CIs for creatinine, NOx, and cGMP clearances
Saline GTN P
Without diabetes
Creatinine 812 (678–974) 588 (416–834) 0.14
NOx 74 (59–92) 58 (33–102) 0.31
cGMP 2,344 (1,542–3,563) 724 (209–2,506) 0.04
With diabetes
Creatinine 776 (597–1,009) 832 (479–1,445) 0.9
NOx 38 (27–53)* 24 (19–31) 0.02
cGMP 3,715 (1,531–9,016) 1,919 (714–4,188) 0.05
Data are means (95% CI). *P  0.002 versus the corresponding mean
values in the group without diabetes.
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the latter, and this was matched by commensurate eleva-
tions in plasma cGMP levels. Our study has also demon-
strated that the administration of GTN significantly
reduces plasma NOx and its urinary elimination in patients
with diabetes but has no significant effect on plasma cGMP
levels. These results provide new information on the
metabolism of NO during cardiac surgery in patients with
diabetes, and the scientific and the clinical implications of
these findings are further discussed below.
NO metabolism during cardiac surgery. The first major
finding of our study is that NO production increased
during cardiac surgery in patients with diabetes, as indi-
cated by the increased plasma levels of NOx and cGMP. In
addition, this study shows that the NOx and cGMP plasma
values were not significantly affected in patients without
diabetes, a finding that is supported by other investigators
(24–26). These results may be explained by the greater NO
production in patients with diabetes under basal condi-
tions (e.g., before surgery) seen in the present study and
also reported by other investigators (5). However, it is
unlikely that the findings are attributable to changes in
renal function, because this was unaffected in both groups
of patients. Sharma et al. (25) have shown that during
cardiac surgery, NO is not elevated in the coronary effluent
of patients with diabetes, suggesting that the source of the
increase in NO production seen in our study is not the
heart.
The reason for the greater NO production in patients
with diabetes is unclear, but an increase in the expression
of NOS in these patients may play a role. High glucose
levels previously shown to increase the expression of
constitutive NOS (27) cannot explain the results of the
present study because blood glucose values were well
controlled at all times (Table 4). It is therefore unlikely
that blood glucose levels could have influenced NOS
expression or activity in these patients. An alternative
explanation for the increase in NO production in the group
with diabetes may be the occurrence of hyperinsulinemia.
Indeed, there is evidence in the literature for insulin
increasing NOS expression (18) and NO production (19–
21); however, the observed increase in plasma insulin
during cardiac surgery in our study was not followed by an
increase in NO in patients without diabetes, and the
time-course of the NO elevation seen in patients with
diabetes was not related to that of insulin (Figs. 1 and 5).
In addition, the infusion of GTN, which blunted NO
production in the group with diabetes, delayed but did not
suppress the elevation of plasma insulin, which further
FIG. 3. Changes in plasma cGMP before (PA, before anesthesia), during
(first 2 h of sampling), and after cardiac surgery in patients with
diabetes (A) and without diabetes (B) receiving an infusion of saline
or GTN at a rate of 1 g  kg–1  min–1 starting 10 min before the
institution of CPB and then maintained for a period of 4 h after the
initiation of CPB. Values were expressed as the arithmetic mean of 10
patients per group, and bars represent the SE.
FIG. 4. Changes in urinary cGMP excretion during (first 2 h of
sampling) and after cardiac surgery in patients without diabetes (A)
and with diabetes (B) receiving an infusion of saline or GTN at a rate
of 1 g  kg–1  min–1 starting 10 min before the institution of CPB and
then maintained for a period of 4 h after the initiation of CPB. Values
were expressed as the arithmetic mean of 10 patients per group, and
bars represent the SE.
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exposes a lack of association between NO production and
hyperinsulinemia during cardiac surgery. It is of interest
that the levels of HbA1 before surgery in patients with
diabetes were within the normal range, confirming that the
metabolic control in this group was adequate. It is also
unlikely that inflammatory factors produced during CPB
mediated the increased NO production, because the time-
course of factors such as proinflammatory cytokines has
no temporal relationship with the time-course of NO (28).
The early increase of NO production suggests an involve-
ment of the constitutive NOS rather than the inducible
NOS, whose expression and synthesis requires several
hours and generates large amounts of NO over long
periods of time (7).
The effect of the increase in NO production during CPB
on the well being of patients was not under investigation in
this study; however, this is still the subject of controversy
in the literature. Several investigators have shown that NO
may be protective to the ischemic myocardium (29–31),
whereas others (32–36) have reported the contrary. In
recent studies, our laboratory has demonstrated that NO
had no detrimental effects on the human myocardium
during ischemia/reperfusion (37), but other studies have
shown that the interaction of NO with other free radical
species promotes oxidative stress (32,33), nitration of
proteins (34,35), and modification of enzyme activity (36)
that can be detrimental. As for NO, the consequences of
increases in cGMP also remain unresolved. Evidence from
experimental heart transplantation (29) has suggested that
elevated cGMP improves myocardial preservation and
graft blood flow. In contrast, other investigators have
reported that activation of the cGMP-dependent protein
kinase G pathway can induce DNA fragmentation and
apoptotic death of cardiac myocytes (33). It is clear that
further work is required to define the role of NO metabo-
lism for patients with diabetes-associated cardiovascular
diseases.
Regulation of NO metabolism by GTN. The second
major finding of this study is that GTN influences NO
metabolism during cardiac surgery. Thus, infusion of GTN
significantly reduced plasma NOx levels in patients with
diabetes. Our study has not revealed the mechanism of
this GTN effect; however, it is possible that GTN down-
regulates constitutive NOS activity, a thesis that finds
support in the observation that NO acts as a negative
feedback modulator of all three NOS isoforms (38–40).
Another possible mechanism is GTN reducing in the
cellular uptake of L-arginine, the precursor of NO. In this
connection, there is recent evidence that GTN suppresses
the uptake of L-arginine by cultured bovine endothelial
cells after 1–4 h of treatment (41). The above two mech-
anisms are not mutually exclusive and may both contrib-
ute to the GTN-induced reduction of plasma NOx in
patients with diabetes (diagram in Fig. 6). It is worth
noting that although the plasma NOx mean values were
not significantly affected by GTN in patients without
diabetes, the observed decrease in urinary NOx excretion
suggests that GTN also reduces NO production in this
group of patients.
The absence of significant changes in plasma cGMP
during cardiac surgery in patients without diabetes and the
increase in plasma values in patients with diabetes were
expected because plasma NOx values were unaffected in
FIG. 5. Changes in plasma insulin before (PA, before anesthesia),
before CPB initiation, during (first 2 h of sampling), and after cardiac
surgery in patients with diabetes (A) and without diabetes (B) receiv-
ing an infusion of saline or GTN at a rate of 1 g  kg–1  min–1 starting
10 min before the institution of CPB and then maintained for a period
of 4 h after the initiation of CPB. Values were expressed as the
arithmetic mean of 10 patients per group, and bars represent the SE.
TABLE 4
Perioperative blood glucose
Saline GTN P
Without diabetes
Pre-CPB 5.7 0.2 6.0 0.4 0.99
End of CPB 7.0 0.6 6.8 0.4 0.84
2 h 7.3  0.6 7.4 0.6 1.99
4 h 8.0  0.5 8.8 0.6 0.96
8 h 6.9  0.4 7.8 0.7 0.78
With diabetes
Pre-CPB 10.9 1.7* 9.4 0.8* 0.62
End of CPB 10.0 0.7* 10.6 0.5* 1.02
2 h 11.0  0.6* 10.8 0.6* 1.23
4 h 10.2  0.4* 10.6 0.4* 0.93
8 h 11.6  0.8* 9.6 0.7* 0.84
Data are means  SD in millimoles per liter. *P  0.05 versus the
corresponding mean values in the group without diabetes.
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the former and elevated in the latter. However, the ob-
served increase in plasma cGMP induced by GTN in
patients without diabetes, in whom plasma NOx was
unaffected by GTN, and the consistent elevation of plasma
cGMP in patients with diabetes, in whom GTN decreased
plasma NOx, is at first sight difficult to interpret. This
dissociation between plasma NOx and cGMP caused by
the administration of GTN in both groups of patients may
find an explanation in the kinetics and metabolism of GTN.
The mechanism by which GTN affects NO metabolism
remains undefined (42,43), but it is possible to speculate
that GTN acts directly or indirectly on the enzyme guan-
ylate cyclase by a mechanism that is NO-independent (Fig.
6). A recent study using isolated rabbit aorta and electron
paramagnetic resonance with an NO spin-trapping agent
has shown that NO is not generated from GTN (44), further
suggesting that the action of GTN on guanylate cyclase
and the generation of cGMP are not mediated by NO. A
recent report by Piatti et al. (45) has shown that in
insulin-resistant nondiabetic subjects, plasma NO is ele-
vated, whereas cGMP is reduced. This report also lends
support to the thesis that under certain conditions cGMP
may be regulated by an NO-independent mechanism.
The mechanism by which GTN reduces cGMP clearance
in patients with and without diabetes and NOx clearance
in those with diabetes is unknown, but it is possible that
some renal mechanism is central to the effects. The re-
duced clearance of cGMP resulted in a significant increase
in plasma cGMP and, as discussed above, this may have
important consequences, such as modulation of the vas-
cular tone and blood flow of tissues, including the kidneys.
The effect of GTN on the regulation of NO and cGMP
formation seen during cardiac surgery in this study may
have important clinical implications for cardiac surgery
and other clinical conditions. It may be particularly rele-
vant in disease states such as diabetes, where basal NO
formation is increased. The mechanism(s) of the GTN
effects remains unclear, as does the clinical consequences
of its actions, and both require further investigation before
NO donor agents are considered as a tool for the modula-
tion of NO and cGMP production.
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FIG. 6. Proposed mode of action of GTN on NO and cGMP formation. , Inhibition; , stimulation.
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